The star of the acquisition is the enzyme replacement therapy INZ-701, being developed for the rare disease ENPP1 deficiency.

Lilly will use Rznomics’ proprietary ribozyme technology to develop RNA editing therapies for congenital hearing loss.

Since Elevidys' first approval in 2023, experts have been clamoring for more data, particularly in older and non-ambulatory ...

The FDA also approved the use of Zynyz as a monotherapy for patients with squamous cell carcinoma of the anal canal who are ...

Over his eight years as CEO, Novo’s sales, profits and share price have almost tripled, the company said. However, the shares ...

As the FDA prepares for a busy Oncologic Drugs Advisory Committee next week, an agency insider told BioSpace that volunteers ...

Sanofi expects to add “a significant number of high-paying jobs” in the U.S. with $20 billion investment through 2030.

The FDA also changed its tune and is now planning to convene an advisory committee to discuss Biohaven’s application.

At a sometimes-contentious U.S. Senate hearing, the Health and Human Services secretary was evasive on the rationale behind ...

AbbVie's Emrelis is the first non-small cell lung cancer therapy approved for patients with high c-Met expression levels who ...

After warnings that the dragged-out process was putting the cell therapy company at risk of bankruptcy, bluebird bio now has ...

Currently trailing Eli Lilly and Structure Therapeutics in the oral weight loss space, Novo Nordisk strikes a deal with ...